Remicade

Remicade is a chimeric monoclonal antibody used for the treatment of psoriasis and psoriatic arthritis.

What is Remicade?

Remicade (also known by its generic name infliximab) is an anti-TNF-alpha drug that was approved by the FDA in May 2005 to treat psoriatic arthritis and in September 2006 to treat chronic severe psoriasis. It is also approved for ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis and Crohn's disease.

For patients with psoriasis or psoriatic arthritis, Remicade is administered in a doctor's office via intravenous infusion at 0, 2, and 6 weeks, then every 8 weeks.

To learn more, please visit the Remicade website.

Treatment Pipeline

Learn about the latest treatment options currently in research.

Get the latest
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Keep up to date with the psoriatic disease field.

Start reading

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.